Evidence map›Paper›PMID 38700207›Full record

ReviewNucleus (Austin, Tex.)2024

Nuclear and degradative functions of the ESCRT-III pathway: implications for neurodegenerative disease.

Olivia Keeley, Alyssa N Coyne

Abstract readReview
In one paragraph

Review in Nucleus (Austin, Tex.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Sorcin couples Annexin A11 recruitment to ESCRT-III assembly for plasma membrane repair.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olivia KeeleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alyssa N CoyneDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Mechanisms of impaired ESCRT-III nuclear surveillance in ALS/FTDR01NS132836 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Alyssa Coyne · 2023 to 2026
$2.3M
Mechanisms of nuclear pore complex homeostasis and injury in ALS/FTD and related neurodegenerative diseasesR00NS123242 · NINDS · JOHNS HOPKINS UNIVERSITY · PI COYNE, ALYSSA · 2022 to 2024
$747k
NINDS NIH HHS R00 NS123242NINDS NIH HHS R01 NS132836
6 · The paper itself

Abstract

The ESCRT machinery plays a pivotal role in membrane-remodeling events across multiple cellular processes including nuclear envelope repair and reformation, nuclear pore complex surveillance, endolysosomal trafficking, and neuronal pruning. Alterations in ESCRT-III functionality have been associated with neurodegenerative diseases including Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Alzheimer's Disease (AD). In addition, mutations in specific ESCRT-III proteins have been identified in FTD/ALS. Thus, understanding how disruptions in the fundamental functions of this pathway and its individual protein components in the human central nervous system (CNS) may offer valuable insights into mechanisms underlying neurodegenerative disease pathogenesis and identification of potential therapeutic targets. In this review, we discuss ESCRT components, dynamics, and functions, with a focus on the ESCRT-III pathway. In addition, we explore the implications of altered ESCRT-III function for neurodegeneration with a primary emphasis on nuclear surveillance and endolysosomal trafficking within the CNS.

Indexed as

Endosomal Sorting Complexes Required for TransportNeurodegenerative DiseasesAnimalsCell NucleusEndosomesFrontotemporal DementiaHumansEndosomal Sorting Complexes Required for TransportAmyotrophic lateral sclerosisendolysosomal traffickingESCRT-III pathwayfrontotemporal dementianeurodegenerative diseasesnuclear pore complexnuclear surveillanceprotein degradation

Identifiers

PMID38700207
PMCPMC11073439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.